With over 8.88 million Novavax, Inc. (NVAX) shares trading Monday and a closing price of $5.15 on the day, the dollar volume was approximately $45.72 million. The shares have shown a negative half year performance of -44.98% and its price on 01/08/24 gained nearly 3.00%. Currently, there are 118.79M common shares owned by the public and among those 111.97M shares have been available to trade.
Insiders at the company have transacted a total of 32 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 21 of these insider trades were purchases, accounting for 72,911 shares. Insider sales of the common stock occurred on 11 occasions, with total insider shares sold totaling 20,087 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Shares of Novavax, Inc. (NASDAQ: NVAX) opened at $4.96, down -$0.04 from a prior closing price of $5.00. However, the script later moved the day high at 5.19, up 3.00%. The company’s stock has a 5-day price change of 7.29% and -32.41% over the past three months. NVAX shares are trading 7.29% year to date (YTD), with the 12-month market performance down to -56.02% lower. It has a 12-month low price of $4.77 and touched a high of $13.70 over the same period. NVAX has an average intraday trading volume of 7.53 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.49%, -10.49%, and -28.80% respectively.
Institutional ownership of Novavax, Inc. (NASDAQ: NVAX) shares accounts for 52.82% of the company’s 118.79M shares outstanding.
It has a market capitalization of $611.77M and a beta (3y monthly) value of 1.46. The earnings-per-share (ttm) stands at -$6.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.21% over the week and 5.66% over the month.
Analysts forecast that Novavax, Inc. (NVAX) will achieve an EPS of $Dynavax Technologies Corporatio for the current quarter, $13.97 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Evaxion Biotech A/S while analysts give the company a high EPS estimate of $ETF Opportunities Trust T-Rex 2. Comparatively, EPS for the current quarter was $NOVONIX Limited – American Depo a year ago. Earnings per share for the fiscal year are expected to increase by 56.61%, and 78.19% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Novavax, Inc. (NVAX) as a “Moderate Buy” at a consensus score of 2.50. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 1 of the 6 advise that investors “hold,” and 1 rated it as a “Sell.”
Looking at the support for the NVAX, a number of firms have released research notes about the stock. B. Riley Securities stated their Buy rating for the stock in a research note on August 09, 2023, with the firm’s price target at $15.
